26 - World Journal of Gastroenterology
26 - World Journal of Gastroenterology
26 - World Journal of Gastroenterology
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Pacifico L et al . Pediatric NAFLD and cardiovascular risk<br />
a report <strong>of</strong> the International Brachial Artery Reactivity Task<br />
Force. J Am Coll Cardiol 2002; 39: 257-<strong>26</strong>5<br />
61 Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S,<br />
Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung<br />
AC. Close relation <strong>of</strong> endothelial function in the human coronary<br />
and peripheral circulations. J Am Coll Cardiol 1995; <strong>26</strong>:<br />
1235-1241<br />
62 Méndez-Sanchez N, Arrese M, Zamora-Valdés D, Uribe M.<br />
Current concepts in the pathogenesis <strong>of</strong> nonalcoholic fatty<br />
liver disease. Liver Int 2007; 27: 423-433<br />
63 Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen<br />
H, Svegliati-Baroni G. From the metabolic syndrome to<br />
NAFLD or vice versa? Dig Liver Dis 2010; 42: 320-330<br />
64 Shoelson SE, Herrero L, Naaz A. Obesity, inflammation,<br />
and insulin resistance. <strong>Gastroenterology</strong> 2007; 132: 2169-2180<br />
65 Stefan N, Kantartzis K, Haring HU. Causes and metabolic<br />
consequences <strong>of</strong> Fatty liver. Endocr Rev 2008; 29: 939-960<br />
66 Tilg H, Moschen AR. Insulin resistance, inflammation, and<br />
non-alcoholic fatty liver disease. Trends Endocrinol Metab<br />
2008; 19: 371-379<br />
67 Chalasani N, Deeg MA, Crabb DW. Systemic levels <strong>of</strong> lipid<br />
peroxidation and its metabolic and dietary correlates in patients<br />
with nonalcoholic steatohepatitis. Am J Gastroenterol<br />
2004; 99: 1497-1502<br />
68 Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir<br />
E, Sanisoglu SY, Erdil A, Ates Y, Aslan M, Musabak U,<br />
Erbil MK, Karaeren N, Dagalp K. Systemic markers <strong>of</strong> lipid<br />
peroxidation and antioxidants in patients with nonalcoholic<br />
Fatty liver disease. Am J Gastroenterol 2005; 100: 850-855<br />
69 Targher G, Bertolini L, Rodella S, Lippi G, Franchini M,<br />
Zoppini G, Muggeo M, Day CP. NASH predicts plasma<br />
inflammatory biomarkers independently <strong>of</strong> visceral fat in<br />
men. Obesity (Silver Spring) 2008; 16: 1394-1399<br />
70 Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl<br />
AM, Johnson RJ, Abdelmalek MF. Fructose consumption as<br />
a risk factor for non-alcoholic fatty liver disease. J Hepatol<br />
2008; 48: 993-999<br />
71 Lindbäck SM, Gabbert C, Johnson BL, Smorodinsky E,<br />
Sirlin CB, Garcia N, Pardee PE, Kistler KD, Schwimmer JB.<br />
Pediatric nonalcoholic fatty liver disease: a comprehensive<br />
review. Adv Pediatr 2010; 57: 85-140<br />
72 Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig<br />
RH. The role <strong>of</strong> fructose in the pathogenesis <strong>of</strong> NAFLD and<br />
the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010; 7:<br />
251-<strong>26</strong>4<br />
73 Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer<br />
AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W,<br />
McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M,<br />
Otokozawa S, Nakajima K, Nakano T, Beysen C, Hellerstein<br />
MK, Berglund L, Havel PJ. Consuming fructose-sweetened,<br />
not glucose-sweetened, beverages increases visceral adiposity<br />
and lipids and decreases insulin sensitivity in overweight/<br />
obese humans. J Clin Invest 2009; 119: 1322-1334<br />
74 Nakajima K, Nakano T, Tanaka A. The oxidative modification<br />
hypothesis <strong>of</strong> atherosclerosis: the comparison <strong>of</strong> atherogenic<br />
effects on oxidized LDL and remnant lipoproteins in<br />
plasma. Clin Chim Acta 2006; 367: 36-47<br />
75 Packard CJ. Small dense low-density lipoprotein and its<br />
role as an independent predictor <strong>of</strong> cardiovascular disease.<br />
Curr Opin Lipidol 2006; 17: 412-417<br />
76 Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto<br />
M, Durazzo M, Fagà E, Silli B, Pagano G. Dietary habits and<br />
their relations to insulin resistance and postprandial lipemia<br />
in nonalcoholic steatohepatitis. Hepatology 2003; 37: 909-916<br />
77 Musso G, Cassader M, Gambino R, Durazzo M, Pagano G.<br />
Association between postprandial LDL conjugated dienes<br />
and the severity <strong>of</strong> liver fibrosis in NASH. Hepatology 2006; 43:<br />
1169-1170<br />
78 Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N,<br />
Pizzolo F, Girelli D, Friso S, Pignatti PF, Corrocher R. Apo-<br />
WJG|www.wjgnet.com<br />
lipoprotein C-III, metabolic syndrome, and risk <strong>of</strong> coronary<br />
artery disease. J Lipid Res 2003; 44: 2374-2381<br />
79 Olivieri O, Stranieri C, Bassi A, Zaia B, Girelli D, Pizzolo<br />
F, Trabetti E, Cheng S, Grow MA, Pignatti PF, Corrocher R.<br />
ApoC-III gene polymorphisms and risk <strong>of</strong> coronary artery<br />
disease. J Lipid Res 2002; 43: 1450-1457<br />
80 Miller M, Rhyne J, Chen H, Beach V, Ericson R, Luthra K,<br />
Dwivedi M, Misra A. APOC3 promoter polymorphisms<br />
C-482T and T-455C are associated with the metabolic syndrome.<br />
Arch Med Res 2007; 38: 444-451<br />
81 Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo<br />
JN, Zhang XM, Dziura J, Lifton RP, Shulman GI. Apolipoprotein<br />
C3 gene variants in nonalcoholic fatty liver disease.<br />
N Engl J Med 2010; 362: 1082-1089<br />
82 Monzavi R, Dreimane D, Geffner ME, Braun S, Conrad B,<br />
Klier M, Kaufman FR. Improvement in risk factors for metabolic<br />
syndrome and insulin resistance in overweight youth<br />
who are treated with lifestyle intervention. Pediatrics 2006;<br />
117: e1111-e1118<br />
83 Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D,<br />
Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle<br />
intervention and antioxidant therapy in children with nonalcoholic<br />
fatty liver disease: a randomized, controlled trial.<br />
Hepatology 2008; 48: 119-128<br />
84 Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte<br />
F, Comparcola D, Sartorelli MR, Angulo P. NAFLD in children:<br />
a prospective clinical-pathological study and effect <strong>of</strong><br />
lifestyle advice. Hepatology 2006; 44: 458-465<br />
85 Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE,<br />
Shulman GI. Reversal <strong>of</strong> nonalcoholic hepatic steatosis,<br />
hepatic insulin resistance, and hyperglycemia by moderate<br />
weight reduction in patients with type 2 diabetes. Diabetes<br />
2005; 54: 603-608<br />
86 Benjaminov O, Beglaibter N, Gindy L, Spivak H, Singer<br />
P, Wienberg M, Stark A, Rubin M. The effect <strong>of</strong> a lowcarbohydrate<br />
diet on the nonalcoholic fatty liver in morbidly<br />
obese patients before bariatric surgery. Surg Endosc 2007; 21:<br />
1423-1427<br />
87 Ebbeling CB, Leidig MM, Sinclair KB, Hangen JP, Ludwig<br />
DS. A reduced-glycemic load diet in the treatment <strong>of</strong> adolescent<br />
obesity. Arch Pediatr Adolesc Med 2003; 157: 773-779<br />
88 Vos MB, Weber MB, Welsh J, Khatoon F, Jones DP, Whitington<br />
PF, McClain CJ. Fructose and oxidized low-density<br />
lipoprotein in pediatric nonalcoholic fatty liver disease: a<br />
pilot study. Arch Pediatr Adolesc Med 2009; 163: 674-675<br />
89 Klein-Platat C, Drai J, Oujaa M, Schlienger JL, Simon C.<br />
Plasma fatty acid composition is associated with the metabolic<br />
syndrome and low-grade inflammation in overweight<br />
adolescents. Am J Clin Nutr 2005; 82: 1178-1184<br />
90 Nobili V, Bedogni G, Alisi A, Pietrobattista A, Risé P, Galli<br />
C, Agostoni C. Docosahexaenoic acid supplementation decreases<br />
liver fat content in children with non-alcoholic fatty<br />
liver disease: double-blind randomised controlled clinical<br />
trial. Arch Dis Child 2011; 96: 350-353<br />
91 Calder PC, Dangour AD, Diekman C, Eilander A, Koletzko<br />
B, Meijer GW, Mozaffarian D, Niinikoski H, Osendarp SJ,<br />
Pietinen P, Schuit J, Uauy R. Essential fats for future health.<br />
Proceedings <strong>of</strong> the 9th Unilever Nutrition Symposium,<br />
<strong>26</strong>-27 May 2010. Eur J Clin Nutr 2010; 64 Suppl 4: S1-S13<br />
92 Koletzko B, Uauy R, Palou A, Kok F, Hornstra G, Eilander<br />
A, Moretti D, Osendarp S, Zock P, Innis S. Dietary intake <strong>of</strong><br />
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)<br />
in children - a workshop report. Br J Nutr 2010; 103: 923-928<br />
93 Tazawa Y, Noguchi H, Nishinomiya F, Takada G. Effect <strong>of</strong><br />
weight reduction on serum transaminase activities in children<br />
with simple obesity. J Pediatr 1996; 128: 587-588<br />
94 Reinehr T, Schmidt C, Toschke AM, Andler W. Lifestyle intervention<br />
in obese children with non-alcoholic fatty liver disease:<br />
2-year follow-up study. Arch Dis Child 2009; 94: 437-442<br />
95 Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO,<br />
3090 July 14, 2011|Volume 17|Issue <strong>26</strong>|